莱西康制药 LXRX
$1.78 +$0.17 (+10.56%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $1.78 0.00%
开盘$1.66
昨收$1.61
当日区间$1.61 – $1.84
成交量3.60M
市值$792.52M
市盈率（TTM）–
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$692,000.00-97.6% YoY
营业利润-$26.54M-810.4% YoY
净利润-$31.78M-1,077.1% YoY
摊薄每股收益-$0.07-800.0% YoY
自由现金流-$9.19M-154.1% YoY
经营现金流-$9.19M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
毛利率99.1%
营业利润率-131.4%
净利率-147.4%
净资产收益率-40.2%
资产收益率-25.7%
投入资本回报率-28.0%
流动比率13.37
负债/资产比率30.2%
现金及投资$190.61M
总负债$57.64M
净现金（净负债）$132.97M
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $692,000.00 | $21.10M | $49.80M | $5.49M | $14.18M |
| 营业总收入 | $692,000.00 | $21.10M | $49.80M | $5.49M | $14.18M |
| 营业成本 | $39,000.00 | $108,000.00 | $274,000.00 | $201,000.00 | $10,000.00 |
| 毛利润 | $653,000.00 | $20.99M | $49.53M | $5.29M | $14.17M |
| 营业费用 | $27.19M | $21.99M | $98.44M | $20.07M | $26.36M |
| 销售及管理费用 | $9.75M | $9.23M | $37.32M | $8.76M | $7.60M |
| 研发费用 | $17.44M | $12.76M | $61.12M | $11.32M | $18.76M |
| 营业利润 | -$26.54M | -$996,000.00 | -$48.91M | -$14.78M | -$12.19M |
| 非经营性利息净收入（支出） | -$886,000.00 | -$47,000.00 | -$1.43M | -$750,000.00 | -$582,000.00 |
| 非经营性利息收入 | $1.72M | $1.54M | $6.91M | $1.28M | $1.57M |
| 非经营性利息支出 | $2.61M | $1.59M | $8.34M | $2.03M | $2.16M |
| 其他收入（支出） | -$4.35M | – | – | – | – |
| 特殊收益（费用） | -$4.35M | – | – | – | – |
| -减：其他特殊支出 | $4.35M | – | – | – | – |
| 税前利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 净利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 持续经营利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 归属母公司净利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 归属普通股股东净利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 基本每股收益 | -$0.07 | $0.00 | -$0.14 | -$0.04 | -$0.04 |
| 摊薄每股收益 | -$0.07 | $0.00 | -$0.14 | -$0.04 | -$0.04 |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $250.06M | $268.82M | $184.99M | $184.99M | $205.93M |
| 流动资产合计 | $196.58M | $186.03M | $101.90M | $101.90M | $122.53M |
| 现金及现金等价物与短期投资 | $190.61M | $170.66M | $96.23M | $96.23M | $115.95M |
| -现金及现金等价物 | $40.92M | $38.09M | $34.33M | $34.33M | $49.66M |
| -短期投资 | $149.69M | $132.57M | $61.90M | $61.90M | $66.29M |
| 应收款 | $1.64M | $11.78M | $2.38M | $2.38M | $2.33M |
| -应收账款 | $1.64M | $11.78M | $2.38M | $2.38M | $2.33M |
| 存货 | $1.20M | $276,000.00 | $281,000.00 | $281,000.00 | $158,000.00 |
| 其他流动资产 | $3.13M | $3.32M | $3.00M | $3.00M | $4.09M |
| 非流动资产合计 | $53.48M | $82.79M | $83.09M | $83.09M | $83.40M |
| 固定资产净值 | $8.57M | $8.88M | $9.18M | $9.18M | $9.49M |
| -固定资产原值 | $11.49M | $11.69M | $11.89M | $11.89M | $12.08M |
| -累计折旧 | -$2.92M | -$2.82M | -$2.71M | -$2.71M | -$2.59M |
| 商誉及其他无形资产 | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M |
| -商誉 | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M |
| 其他非流动资产 | $368,000.00 | $29.37M | $29.37M | $29.37M | $29.37M |
| 负债合计 | $75.54M | $65.96M | $77.45M | $77.45M | $85.77M |
| 流动负债合计 | $14.71M | $9.90M | $20.87M | $20.87M | $21.72M |
| 应付款 | $2.34M | $3.00M | $3.08M | $3.08M | $3.80M |
| -应付账款 | $2.34M | $3.00M | $3.08M | $3.08M | $3.80M |
| 一年内应计费用 | $6.83M | $2.51M | $5.13M | $5.13M | $7.19M |
| 短期债务及融资租赁负债 | $1.64M | $1.64M | $6.24M | $6.24M | $1.64M |
| -一年内到期融资租赁负债 | $1.64M | $1.64M | $1.64M | $1.64M | $1.64M |
| 非流动负债合计 | $60.83M | $56.07M | $56.58M | $56.58M | $64.05M |
| 长期债务及融资租赁负债 | $57.64M | $56.07M | $56.58M | $56.58M | $56.51M |
| -长期债务 | $51.44M | $49.68M | $49.41M | $49.41M | $56.51M |
| -长期融资租赁负债 | $6.20M | $6.38M | $7.17M | $7.17M | – |
| 其他非流动负债 | $3.19M | – | – | – | $7.54M |
| 股东权益合计 | $174.53M | $202.86M | $107.54M | $107.54M | $120.16M |
| 股东权益 | $174.53M | $202.86M | $107.54M | $107.54M | $120.16M |
| 股本 | $447,000.00 | $430,000.00 | $366,000.00 | $366,000.00 | $366,000.00 |
| -普通股 | $447,000.00 | $426,000.00 | $366,000.00 | $366,000.00 | $366,000.00 |
| -优先股 | $0.00 | $4,000.00 | $0.00 | $0.00 | $0.00 |
| 资本公积 | $2.23B | $2.22B | $2.13B | $2.13B | $2.13B |
| 留存收益 | -$2.05B | -$2.02B | -$2.02B | -$2.02B | -$2.00B |
| 减：库存股 | $2.84M | $2.84M | $5.19M | $5.19M | $5.19M |
| 不影响留存收益的损益 | -$204,000.00 | -$130,000.00 | $30,000.00 | $30,000.00 | $29,000.00 |
| -一年内到期债务 | – | – | $4.60M | $4.60M | – |
| 一年内递延负债 | – | – | – | – | $4.30M |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | -$9.19M | -$14.73M | -$67.85M | -$17.23M | -$23.83M |
| 持续经营经营活动现金流净额 | -$9.19M | -$14.73M | -$67.85M | -$17.23M | -$23.83M |
| 持续经营净利润 | -$31.78M | -$1.04M | -$50.34M | -$15.53M | -$12.77M |
| 折旧、折耗与摊销 | $102,000.00 | $110,000.00 | $621,000.00 | $118,000.00 | $151,000.00 |
| 其他非现金项目 | $1.01M | $100,000.00 | -$42,000.00 | $332,000.00 | $384,000.00 |
| 营运资金变动 | $14.51M | -$16.41M | -$26.89M | -$4.55M | -$14.31M |
| -应收款变动 | $10.14M | -$9.40M | $1.09M | -$50,000.00 | -$151,000.00 |
| -存货变动 | -$920,000.00 | $5,000.00 | -$50,000.00 | -$123,000.00 | $10,000.00 |
| -预付资产变动 | $191,000.00 | -$319,000.00 | $1.53M | $1.08M | -$358,000.00 |
| -应付账款及应计费用变动 | $4.90M | -$6.90M | -$30.22M | -$5.65M | -$14.00M |
| -其他流动资产变动 | $202,000.00 | $195,000.00 | $757,000.00 | $190,000.00 | $191,000.00 |
| 投资活动现金流净额 | -$16.46M | -$70.26M | $113.02M | $4.83M | $52.13M |
| 持续经营投资活动现金流净额 | -$16.46M | -$70.26M | $113.02M | $4.83M | $52.13M |
| 投资购置及出售净额 | -$16.46M | -$70.26M | $113.02M | $4.83M | $52.13M |
| 筹资活动现金流 | -$512,000.00 | $88.76M | -$48.50M | -$2.93M | $0.00 |
| 持续经营筹资活动现金流净额 | -$512,000.00 | $88.76M | -$48.50M | -$2.93M | $0.00 |
| 债务发行及偿还净额 | $739,000.00 | -$5.00M | -$48.00M | -$3.00M | $0.00 |
| 普通股发行净额 | $1.02M | $70.05M | -$572,000.00 | $0.00 | -$572,000.00 |
| 优先股发行净额 | $0.00 | $26.55M | $0.00 | $0.00 | $0.00 |
| 其他筹资费用净额 | -$2.27M | -$2.84M | – | – | – |
| 期末现金余额 | $40.92M | $67.09M | $63.33M | $63.33M | $78.66M |
| 现金净变动 | -$26.17M | $3.76M | -$3.33M | -$15.33M | $28.29M |
| 期初现金余额 | $67.09M | $63.33M | $66.66M | $78.66M | $50.36M |
| 自由现金流 | -$9.19M | -$14.73M | -$67.85M | -$17.23M | -$23.83M |
| 固定资产购置及出售净额 | – | – | $0.00 | $0.00 | – |
| 股票期权行使所得 | – | – | $73,000.00 | – | – |
暂无评论——快来第一个聊聊 LXRX。